Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer

Abstract

Thyroid cancer is the most common type of endocrine neoplasia. Despite recent breakthroughs in treatment of the disease, the treatment of advanced, progressive thyroid cancers remains challenging with limited therapeutic options available. In this study, we evaluated a novel and orally bioavailable small-molecule multiple tyrosine kinases inhibitor, AL3810, in preclinical models of thyroid cancer in vitro and in vivo. AL3810 (2-5 μmol/L) dose-dependently inhibited the proliferation of human thyroid cancer cell lines TT, SW579 and TPC-1 in vitro with IC values ranging from 0.59 to 7.03 μmol/L. Specifically, this agent dose-dependently arrested the thyroid cancer cells in the G phase and induced apoptosis. Furthermore, AL3810 dose-dependently inhibited the migration and invasion of SW579 and TPC-1 cells in vitro. In SW579 and TT xenograft models, oral administration of AL3810 (5-20 mg·kg·d) for 21 d potently inhibited the tumor growth; immunohistochemical staining revealed that the antitumor activity of AL3810 was closely correlated with its anti-angiogenesis effect, as evidenced by a dose-dependent reduction of microvessels in tumor tissues. To assess the therapeutic potential of AL3810 in treating thyroid cancer involving RET gene fusion, we showed that AL3810 (1-10 μmol/L) dose-dependently inhibited the proliferation of RET-driven Baf3 cell line Baf3-CCDC6-RET, and the auto-phosphorylation of RET in these cells. Our data suggest that AL3810 is a promising agent for the treatment of thyroid cancer.

Boosting the Photovoltaic Performance and Thermal Stability of Organic Solar Cells via an Insulating Fluoropolymer Additive

“…This difference may be attributed to the different tacticity of the polymers, which affects the crystallization and orientation of the polymers, [26–28] and further changes glass transition and thermal decomposition behavior [29–32] . In addition, the experimental test conditions may also affect the measured T g and T d [33–36] …”

A pentapeptide enabled AL3810 liposome-based glioma-targeted therapy with immune opsonic effect attenuated

“…VEGF/VEGFR and FGF/FGFR signaling of glioma were pervasively documented before 4 , 5 , 6 , consequently a number of VEGF/VEGFR and FGF/FGFR-targeting agents have been trialed for glioma treatment. AL3810 could block VEGFR and FGFR, contributing to down regulation of receptor expression 25 . U87 MG cells incubated with AL3810 formulations decreased VEGFR expression to varying degrees.…”

Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment

“…Lucitanib (E3810 or AL3810) is a reversible, ATP‐competitive TKI that targets FGFR1‐2 and VEGFR1‐3 in the nM range and exerts antitumour activity in multiple preclinical models, including colon, ovarian, renal and thyroid carcinoma and breast cancer 40,163,164 . Soria JC demonstrated the clinical benefit of lucitanib used in both FGF‐aberrant and angiogenesis‐sensitive populations, with 50% (six of 12) achieved partial response (PR) in FGF‐aberrant breast cancer patients 165 .…”